Zurich, January 18, 2026, 20:45 CET — The market has closed.
Novartis shares rose close to 1% on Friday after the Swiss pharma giant announced that U.S. regulators had granted a Breakthrough Therapy designation to ianalumab, its drug candidate for Sjögren’s disease. The stock finished at 115.60 Swiss francs on the SIX Swiss Exchange. MarketWatch
The designation is important because it aims to accelerate development and review for drugs targeting serious illnesses when early clinical data indicate they might outperform existing treatments. It also often leads to more frequent FDA engagement and a quicker route toward submitting an application — though it doesn’t equate to approval. U.S. Food and Drug Administration
Swiss trading kicks off again Monday, and investors will quickly find out if Friday’s move has legs in a market growing more selective about healthcare stocks. The Swiss Market Index dropped 0.47% on Friday, even as Europe’s healthcare sector ended higher. That leaves Novartis room to stand out on stock-specific news. MarketWatch
Novartis announced it will start global regulatory submissions for ianalumab early in 2026, positioning the drug as the first targeted treatment in an area with few options. “This designation recognises the potential for ianalumab to improve care for people with Sjögren’s disease, who lack effective options,” said Angelika Jahreis, global head of development for immunology at Novartis. Novartis
U.S. investors will get their next trading opportunity a day later than normal. Markets are shut Monday in observance of Martin Luther King Jr. Day, Reuters reported. Reuters
Novartis’ U.S.-listed ADRs climbed to $144.34, marking a roughly 0.8% gain from the previous close, per market data.
Broker sentiment stayed divided. UBS analyst Matthew Weston held onto a Neutral rating but bumped up his target price to 116 Swiss francs, according to a dpa-AFX note published on MarketScreener. MarketScreener
Breakthrough Therapy designation isn’t a guaranteed fast track to market. Timelines often slip, regulators may demand additional data, and late-stage trials can come up short — any of which can flip a Friday rally into a Monday selloff.
Novartis will report its fourth-quarter and full-year results on Feb. 4, also providing updates on guidance and pipeline milestones. Novartis
